What is Replimune Group, Inc.'s earnings per share (EPS)?

Replimune Group, Inc. (REPL) reported diluted earnings per share of -$3.38 for fiscal year 2026. This represents a -10.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Replimune Group, Inc. (REPL) Financials

REPL

FY2026 annual

Net Income -$313.9M -26.9% YoY

EPS (Diluted) -$3.38 -10.1% YoY

Free Cash Flow -$284.6M -43.0% YoY

Operating Cash Flow -$280.3M -45.8% YoY

Market Cap $1.1B as of Oct 14, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 10.8x on $105.6M equity, Q1 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE March

Newest figures come from the 10-Q for Q1 FY2027, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the REPL SEC filings page.

This page shows Replimune Group, Inc. (REPL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI REPL FY2026 2026-10-04

The statements depict a development-stage business funded by external cash, with operating losses widening and balance-sheet flexibility shrinking.

In FY2026, free cash flow was -$285M despite only $4.2M of capital spending, showing that the cash drain primarily reflects development operations rather than heavy physical reinvestment. A $311M investing inflow plus $66.3M of financing inflow outweighed that operating use, so the period’s cash movement depended on sources outside operations.

Net loss reached $314M in FY2026 as R&D spending reached $221M; the cost base is expanding before reported revenue appears.

Total assets fell from $551M in FY2025 to $332M in FY2026, shrinking the resource base available to absorb ongoing losses. Debt-to-equity reached 0.5x while the reported liquidity comparison was 11.5 months of the latest annual operating outflow, showing less equity cushion and greater reliance on replenished external cash.

Financial Health Signals

Financial health score not available

Replimune Group, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

Replimune Group, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Replimune Group, Inc. reported a net loss of $313.9M while operations used $280.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Replimune Group, Inc. reported an operating loss of $319.9M against $6.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$67.3M

YoY+24.8%

Replimune Group, Inc.'s EBITDA was -$67.3M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 24.8% from the same quarter a year earlier.

Net Income

-$69.8M

YoY+19.5%

Replimune Group, Inc. reported -$69.8M in net income in Q1 2027. This represents an increase of 19.5% from the same quarter a year earlier.

EPS (Diluted)

-$0.72

YoY+24.2%

QoQ+5.3%

Replimune Group, Inc. earned -$0.72 per diluted share (EPS) in Q1 2027. This represents an increase of 24.2% from the same quarter a year earlier. Against the prior quarter it is up 5.3%.

Revenue

Not reported for Q1 2027.

Cash & Balance Sheet

Free Cash Flow

-$75.7M

YoY+5.0%

QoQ-34.8%

Replimune Group, Inc. recorded an outflow of $75.7M in free cash flow in Q1 2027, representing a cash shortfall after capex. This represents an increase of 5.0% from the same quarter a year earlier. Against the prior quarter it is down 34.8%.

Cash & Debt

$185.4M

YoY+90.4%

QoQ-11.3%

5Y CAGR-0.8%

Replimune Group, Inc. held $185.4M in cash against $84.1M in long-term debt as of Q1 2027.

Shares Outstanding

94M

YoY+20.7%

QoQ+12.2%

5Y CAGR+15.0%

Replimune Group, Inc. had 94M shares outstanding in Q1 2027. This represents an increase of 20.7% from the same quarter a year earlier. Against the prior quarter it is up 12.2%.

Dividends Per Share

Not reported for Q1 2027.

Margins & Returns

Return on Equity

-66.0%

YoY-40.3pp

Replimune Group, Inc.'s ROE was -66.0% in Q1 2027, measuring profit generated per dollar of shareholder equity. This is down 40.3 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2027.

Operating Margin

Not reported for Q1 2027.

Net Margin

Not reported for Q1 2027.

Capital Allocation

R&D Spending

$49.3M

YoY-14.8%

Replimune Group, Inc. invested $49.3M in research and development in Q1 2027. This represents a decrease of 14.8% from the same quarter a year earlier.

Capital Expenditures

$6K

YoY-99.8%

QoQ+20.0%

5Y CAGR-54.0%

Replimune Group, Inc. invested $6K in capex in Q1 2027, funding long-term assets and infrastructure. This represents a decrease of 99.8% from the same quarter a year earlier. Against the prior quarter it is up 20.0%.

Share Buybacks

Not reported for Q1 2027.

REPL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REPL quarterly income statement

Metric	TTM	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
R&D Expenses	N/A	$221.2M+16.8%	$189.4M+8.3%	$175.0M+38.3%	$126.5M+59.1%	$79.5M+40.2%	$56.8M+46.4%	$38.8M+74.8%	$22.2M+64.1%	$13.5M+94.9%	$6.9M
SG&A Expenses	N/A	$98.7M+36.8%	$72.2M+20.7%	$59.8M+18.3%	$50.6M+30.4%	$38.8M+67.1%	$23.2M+33.1%	$17.4M+98.8%	$8.8M+53.6%	$5.7M+110.7%	$2.7M
Operating Income	N/A	-$319.9M-22.3%	-$261.6M-11.4%	-$234.8M-32.6%	-$177.1M-49.7%	-$118.3M-48.0%	-$80.0M-42.3%	-$56.2M-81.6%	-$30.9M-60.9%	-$19.2M-99.3%	-$9.6M
EBITDA	N/A	-$316.6M-22.6%	-$258.1M-11.2%	-$232.1M-32.9%	-$174.6M-50.3%	-$116.2M-48.5%	-$78.2M-40.6%	-$55.7M-80.7%	-$30.8M-61.1%	-$19.1M-100.7%	-$9.5M
Interest Expense	N/A	$6.8M+17.7%	$5.8M+28.4%	$4.5M+129.1%	$2.0M	$0-100.0%	$818K+11.4%	$734K	N/A	N/A	N/A
Income Tax	N/A	-$551K-217.7%	$468K+14.7%	$408K+41.7%	$288K	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$313.9M-26.9%	-$247.3M-14.6%	-$215.8M-23.8%	-$174.3M-47.7%	-$118.0M-46.0%	-$80.9M-53.7%	-$52.6M-70.7%	-$30.8M-56.5%	-$19.7M-155.7%	-$7.7M
EPS (Basic)	N/A	-$3.38-10.1%	-$3.07+5.2%	-$3.24-8.4%	-$2.99-32.3%	-$2.26-29.1%	-$1.75	N/A	N/A	N/A	N/A
EPS (Diluted)	-$3.15	-$3.38-10.1%	-$3.07+5.2%	-$3.24-8.4%	-$2.99-32.3%	-$2.26-29.1%	-$1.75	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	93M+15.2%	81M+21.0%	67M+14.4%	58M+11.5%	52M+12.9%	46M	N/A	N/A	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
R&D Expenses	$49.3M-14.8%	N/A	$53.1M+10.7%	$57.9M+33.2%	$57.8M+34.6%	N/A	$48.0M+12.0%	$43.4M-11.5%
SG&A Expenses	$19.0M-41.8%	N/A	$18.7M+4.0%	$26.4M+70.8%	$32.6M+126.3%	N/A	$18.0M+31.6%	$15.5M+5.0%
Operating Income	-$68.2M+24.5%	N/A	-$71.9M-8.9%	-$84.3M-43.1%	-$90.4M-57.6%	N/A	-$66.0M-16.8%	-$58.9M+7.7%
EBITDA	-$67.3M+24.8%	N/A	-$71.1M-9.3%	-$83.5M-43.9%	-$89.5M-58.1%	N/A	-$65.0M-16.4%	-$58.0M+8.1%
Interest Expense	$2.6M+75.0%	N/A	$1.5M+1.1%	$1.5M+3.5%	$1.5M+3.4%	N/A	$1.4M+43.3%	$1.4M+50.6%
Income Tax	N/A	N/A	-$311K-154.1%	$0	$0	N/A	$575K+21.6%	$0+100.0%
Net Income	-$69.8M+19.5%	N/A	-$70.9M-6.9%	-$83.1M-56.6%	-$86.7M-61.2%	N/A	-$66.3M-29.8%	-$53.1M+11.6%
EPS (Basic)	-$0.72+24.2%	-$0.76+7.3%	-$0.77+2.5%	-$0.90-32.4%	-$0.95-21.8%	-$0.820.0%	-$0.79-2.6%	-$0.68+24.4%
EPS (Diluted)	-$0.72+24.2%	-$0.76+7.3%	-$0.77+2.5%	-$0.90-32.4%	-$0.95-21.8%	-$0.820.0%	-$0.79-2.6%	-$0.68+24.4%
Diluted Shares (Avg)	97M+5.8%	N/A	92M+10.4%	92M+17.0%	92M+32.3%	N/A	83M+25.3%	79M+18.0%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

REPL Balance Sheet

REPL quarterly balance sheet

Metric	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$332.4M-39.7%	$551.3M+13.0%	$487.7M-24.6%	$646.6M+40.2%	$461.2M-15.1%	$543.1M+132.0%	$234.1M+51.7%	$154.3M+136.9%	$65.2M	N/A
Current Assets	$279.1M-43.7%	$495.9M+14.3%	$433.7M-26.8%	$592.6M+46.7%	$404.0M-16.5%	$483.7M+177.6%	$174.3M+23.6%	$141.0M+117.9%	$64.7M	N/A
Cash & Equivalents	$209.0M+88.1%	$111.1M+49.2%	$74.5M-49.2%	$146.6M+38.4%	$105.9M-42.0%	$182.5M+206.8%	$59.5M+131.5%	$25.7M+46.2%	$17.6M-14.9%	$20.7M
Short-Term Investments	$59.9M-83.9%	$372.7M+7.6%	$346.2M-20.7%	$436.8M+50.8%	$289.7M-1.4%	$293.8M+169.4%	$109.1M0.0%	$109.1M+148.2%	$44.0M	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$166.2M+22.7%	$135.5M+19.7%	$113.2M+24.0%	$91.3M+82.7%	$50.0M+12.6%	$44.4M-11.9%	$50.4M+205.9%	$16.5M-82.3%	$93.2M	N/A
Current Liabilities	$58.2M-6.6%	$62.4M+54.2%	$40.4M+19.6%	$33.8M+63.0%	$20.8M+42.7%	$14.5M+22.5%	$11.9M+20.1%	$9.9M+91.4%	$5.2M	N/A
Non-Current Liabilities	$108.0M+47.7%	$73.1M+0.5%	$72.8M+26.6%	$57.5M+96.8%	$29.2M-2.1%	$29.8M-22.5%	$38.5M+484.7%	$6.6M-92.5%	$88.1M	N/A
Long-Term Debt	$83.3M+79.6%	$46.4M+3.5%	$44.8M+56.4%	$28.6M	$0	N/A	$9.8M	N/A	N/A	N/A
Total Equity	$166.2M-60.0%	$415.8M+11.0%	$374.5M-32.6%	$555.3M+35.0%	$411.2M-17.5%	$498.7M+171.5%	$183.7M+33.3%	$137.9M+591.2%	-$28.1M-143.8%	-$11.5M
Retained Earnings	-$1.3B-33.1%	-$948.6M-35.3%	-$701.3M-44.4%	-$485.5M-56.0%	-$311.2M-61.1%	-$193.2M-72.0%	-$112.3M-87.9%	-$59.8M-106.6%	-$28.9M	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Total Assets	$252.4M-46.2%	$332.4M-39.7%	$333.6M-44.7%	$389.4M-21.8%	$469.5M-12.2%	$551.3M+13.0%	$603.6M+13.3%	$498.2M-11.4%
Current Assets	$200.8M-51.4%	$279.1M-43.7%	$280.4M-48.8%	$333.7M-24.6%	$413.4M-13.9%	$495.9M+14.3%	$547.6M+14.3%	$442.6M-12.9%
Cash & Equivalents	$185.4M+90.4%	$209.0M+88.1%	$123.0M-28.6%	$102.3M-9.9%	$97.4M-35.8%	$111.1M+49.2%	$172.2M+76.4%	$113.5M+49.3%
Short-Term Investments	$10.0M-96.7%	$59.9M-83.9%	$146.2M-59.9%	$221.3M-30.5%	$306.0M-3.6%	$372.7M+7.6%	$364.3M-1.2%	$318.6M-24.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$146.8M+10.6%	$166.2M+22.7%	$123.1M+1.5%	$126.1M+8.0%	$132.8M+22.4%	$135.5M+19.7%	$121.3M+8.9%	$116.7M+20.1%
Current Liabilities	$38.4M-35.5%	$58.2M-6.6%	$50.1M+4.6%	$52.9M+20.8%	$59.6M+66.9%	$62.4M+54.2%	$47.9M+23.9%	$43.8M+9.9%
Non-Current Liabilities	$108.4M+48.0%	$108.0M+47.7%	$73.0M-0.5%	$73.2M+0.4%	$73.2M+0.5%	$73.1M+0.5%	$73.4M+0.9%	$73.0M+27.1%
Long-Term Debt	$84.1M+79.8%	$83.3M+79.6%	$47.6M+3.6%	$47.2M+3.6%	$46.8M+3.5%	$46.4M+3.5%	$46.0M+3.4%	$45.6M+56.3%
Total Equity	$105.6M-68.6%	$166.2M-60.0%	$210.5M-56.4%	$263.3M-31.0%	$336.7M-21.0%	$415.8M+11.0%	$482.4M+14.4%	$381.5M-18.0%
Retained Earnings	-$1.3B-28.7%	-$1.3B-33.1%	-$1.2B-36.0%	-$1.1B-38.4%	-$1.0B-37.1%	-$948.6M-35.3%	-$874.4M-35.3%	-$808.1M-35.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

REPL Cash Flow Statement

REPL quarterly cash flow statement

Metric	TTM	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	-$279.1M	-$280.3M-45.8%	-$192.3M-3.7%	-$185.5M-44.8%	-$128.1M-55.8%	-$82.2M-33.9%	-$61.4M-1.4%	-$60.6M-138.6%	-$25.4M-58.5%	-$16.0M-126.3%	-$7.1M
Depreciation & Amortization	N/A	$3.3M-4.9%	$3.5M+31.9%	$2.7M+8.5%	$2.4M+14.0%	$2.1M+25.5%	$1.7M+221.0%	$533K+260.1%	$148K+35.8%	$109K-10.7%	$122K
Stock-Based Compensation	N/A	$32.3M-7.9%	$35.0M+2.7%	$34.1M+21.3%	$28.1M+16.0%	$24.3M+105.7%	$11.8M+52.3%	$7.7M+183.6%	$2.7M+236.2%	$812K+290.4%	$208K
Capital Expenditures	$1.5M	$4.2M-36.8%	$6.7M+18.1%	$5.7M+149.4%	$2.3M-2.8%	$2.3M-2.3%	$2.4M-63.4%	$6.5M+151.5%	$2.6M+1811.8%	$136K-42.9%	$238K
Free Cash Flow	-$280.5M	-$284.6M-43.0%	-$198.9M-4.1%	-$191.1M-46.7%	-$130.3M-54.2%	-$84.5M-32.5%	-$63.8M+4.9%	-$67.1M-139.8%	-$28.0M-73.2%	-$16.1M-120.8%	-$7.3M
Investing Cash Flow	$295.8M	$310.8M+1406.3%	-$23.8M-124.5%	$97.2M+168.2%	-$142.5M-7790.5%	-$1.8M+99.0%	-$188.8M-3507.4%	-$5.2M+92.1%	-$65.9M-49.7%	-$44.0M-18406.7%	-$238K
Financing Cash Flow	$67.3M	$66.3M-73.7%	$252.4M+1450.1%	$16.3M-94.8%	$311.3M+4618.1%	$6.6M-98.2%	$372.5M+271.8%	$100.2M-1.2%	$101.4M+85.2%	$54.8M+265.0%	$15.0M

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Operating Cash Flow	-$75.7M+1.7%	-$56.2M-4.5%	-$66.0M-30.1%	-$81.2M-110.2%	-$77.0M-56.6%	-$53.7M-16.4%	-$50.7M-7.6%	-$38.6M+11.4%
Depreciation & Amortization	$937K+7.3%	$769K-9.3%	$800K-20.0%	$800K-11.1%	$873K+18.6%	$848K+20.3%	$1.0M+42.9%	$900K+28.6%
Stock-Based Compensation	$7.7M-12.4%	N/A	$7.0M-18.4%	$8.3M-3.6%	$8.8M-7.5%	N/A	$8.6M+4.8%	$8.7M-5.1%
Capital Expenditures	$6K-99.8%	$5K-99.6%	$135K-92.5%	$1.3M-35.6%	$2.7M+64.2%	$1.1M-34.8%	$1.8M+4.7%	$2.1M+18.8%
Free Cash Flow	-$75.7M+5.0%	-$56.2M-2.4%	-$66.1M-25.9%	-$82.6M-102.7%	-$79.8M-56.9%	-$54.9M-14.5%	-$52.5M-7.5%	-$40.7M+10.2%
Investing Cash Flow	$50.0M-23.1%	$86.5M+1223.5%	$75.1M+262.2%	$84.2M+18277.5%	$65.0M+118.5%	-$7.7M-133.2%	-$46.3M-185.8%	$458K-96.4%
Financing Cash Flow	$800K+606.3%	$55.7M+42279.5%	$10.5M-93.3%	$324K+930.8%	-$158K-100.2%	-$132K-1.5%	$155.9M+948.6%	-$39K-108.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

REPL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

REPL quarterly financial ratios

Metric	FY26DEF 14A	FY25DEF 14A	FY24DEF 14A	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Return on Equity	-188.9%-129.4pp	-59.5%-1.8pp	-57.6%-26.2pp	-31.4%-2.7pp	-28.7%-12.5pp	-16.2%+12.4pp	-28.6%-6.3pp	-22.4%	N/A	N/A
Return on Assets	-94.4%-49.6pp	-44.9%-0.6pp	-44.3%-17.3pp	-27.0%-1.4pp	-25.6%-10.7pp	-14.9%+7.6pp	-22.5%-2.5pp	-20.0%+10.3pp	-30.2%	N/A
Current Ratio	4.79-3.2x	7.95-2.8x	10.72-6.8x	17.52-1.9x	19.46-13.8x	33.25+18.6x	14.68+0.4x	14.26+1.7x	12.53	N/A
Debt-to-Equity	0.50+0.4x	0.110.0x	0.12+0.1x	0.05+0.1x	0.00-0.1x	0.090.0x	0.05-0.1x	0.12	N/A	N/A

Metric	Q1'2710-Q	Q4'2610-Q	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q
Return on Equity	-66.0%-40.3pp	N/A	-33.7%-19.9pp	-31.6%-17.6pp	-25.8%-13.1pp	N/A	-13.8%-1.6pp	-13.9%-1.0pp
Return on Assets	-27.6%-9.2pp	N/A	-21.3%-10.3pp	-21.3%-10.7pp	-18.5%-8.4pp	N/A	-11.0%-1.4pp	-10.7%0.0pp
Current Ratio	5.23-1.7x	4.79-3.2x	5.60-5.8x	6.31-3.8x	6.94-6.5x	7.95-2.8x	11.43-1.0x	10.11-2.6x
Debt-to-Equity	0.80+0.7x	0.50+0.4x	0.23+0.1x	0.18+0.1x	0.140.0x	0.110.0x	0.100.0x	0.12+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Replimune Group, Inc. REPL	FY2026	N/A	-$313.9M	N/A	$1.1B	—
Bicycle Therapeutics plc BCYC	FY2025	$72.6M	-$219.0M	N/A	$254.1M	60/100
REGENXBIO Inc. RGNX	FY2025	$170.4M	-$193.9M	N/A	$479.3M	64/100
Corvus Pharmaceuticals, Inc. CRVS	FY2025	N/A	-$15.3M	N/A	$791.6M	—
iTeos Therapeutics, Inc. ITOS	FY2024	$35.0M	-$134.4M	N/A	$448.7M	33/100

Where Replimune Group, Inc. Ranks

Frequently Asked Questions

Is Replimune Group, Inc. profitable?

No, Replimune Group, Inc. (REPL) reported a net income of -$313.9M in fiscal year 2026.

What is Replimune Group, Inc.'s EBITDA?

Replimune Group, Inc. (REPL) had EBITDA of -$316.6M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Replimune Group, Inc. have?

As of fiscal year 2026, Replimune Group, Inc. (REPL) had $209.0M in cash and equivalents against $83.3M in long-term debt.

What is Replimune Group, Inc.'s return on equity (ROE)?

Replimune Group, Inc. (REPL) has a return on equity of -188.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Replimune Group, Inc.'s free cash flow?

Replimune Group, Inc. (REPL) recorded an outflow of $284.6M in free cash flow during fiscal year 2026. This represents a -43.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Replimune Group, Inc.'s operating cash flow?

Replimune Group, Inc. (REPL) recorded an outflow of $280.3M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are Replimune Group, Inc.'s total assets?

Replimune Group, Inc. (REPL) had $332.4M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Replimune Group, Inc.'s capital expenditures?

Replimune Group, Inc. (REPL) invested $4.2M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Replimune Group, Inc. spend on research and development?

Replimune Group, Inc. (REPL) invested $221.2M in research and development during fiscal year 2026.

How many shares does Replimune Group, Inc. have outstanding?

Replimune Group, Inc. (REPL) had 84M shares outstanding as of fiscal year 2026.

What is Replimune Group, Inc.'s current ratio?

Replimune Group, Inc. (REPL) had a current ratio of 4.79 as of fiscal year 2026, which is generally considered healthy.

What is Replimune Group, Inc.'s debt-to-equity ratio?

Replimune Group, Inc. (REPL) had a debt-to-equity ratio of 0.50 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Replimune Group, Inc.'s return on assets (ROA)?

Replimune Group, Inc. (REPL) had a return on assets of -94.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Replimune Group, Inc.'s P/E ratio?

Replimune Group, Inc. (REPL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $1.1B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Replimune Group, Inc.'s price-to-sales ratio?

Replimune Group, Inc. (REPL) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.1B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Replimune Group, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, Replimune Group, Inc. (REPL) held $268.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $280.3M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Replimune Group, Inc.'s Piotroski F-Score?

Replimune Group, Inc. (REPL) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Replimune Group, Inc.'s earnings high quality?

Replimune Group, Inc. (REPL) reported a net loss of $313.9M while operations used $280.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Replimune Group, Inc. cover its interest payments?

Replimune Group, Inc. (REPL) reported an operating loss of $319.9M against $6.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.